Frontotemporal dementia: clinical features, diagnosis, and treatment
https://doi.org/10.46563/2686-8997-2022-3-1-14-24
Abstract
Frontotemporal dementia (FTD) is the second most common cause of neurodegenerative dementia affecting patients before 65. The classic clinical phenotypes of the disease include the behavioral variant of FTD and variants with a predominant speech disorder - primary progressive aphasia (agrammatic, semantic and logopenic variants). Often, classic FTD phenotypes can be associated with atypical parkinsonism such as corticobasal syndrome and progressive supranuclear palsy, and motor neuron disease. The disease is also heterogeneous from a pathophysiological point of view. It may be based on one of three pathological processes, while up to 40% of cases have a hereditary burden. Currently there have been described mutations in about 20 genes associated with FTD. Given the wide variety of clinical presentation, FTD may be a phenocopy of other diseases, which makes it difficult to diagnose, complicates the differential diagnosis and delays the correct diagnosis for several years. Poor awareness of the disease and its clinical features among clinicians is one of the reasons for the lack of data on the prevalence of the disease in the Russian Federation. In addition, the identification of families with genetic forms of the disease and asymptomatic carriers is an important step in the formation of a strategy for helping this category of patients when approaches to pathogenetic therapy appear. This review of the literature presents modern ideas about the clinical picture, features of diagnosis and differential diagnosis of various clinical variants of FTD. The current understanding of approaches to pharmacological and non-pharmacological therapy is also presented.
About the Authors
Yuliya A. Shpilyukova
Research Center of Neurology
Russian Federation
Russian Federation
MD, PhD, junior fellow, neurologist, 5th neurological department, Research Center of Neurology, Moscow, 125367, Russian Federation.
e-mail: jshpilyukova@gmail.com
Ekaterina Yu. Fedotova
Research Center of Neurology
Russian Federation
Russian Federation
References
1. Hodges J.R. Frontotemporal dementia (Pick’s disease): clinical features and assessment. Neurology. 2001; 56(Suppl. 4): S6–10. https://doi.org/10.1212/WNL.56.suppl_4.S6
2. Rohrer J.D., Guerreiro R., Vandrovcova J., Uphill J., Reiman D., Beck J., et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009; 73(18): 1451–6. https://doi.org/10.1212/WNL.0b013e3181bf997a
3. Mackenzie I.R., Neumann M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J. Neurochem. 2016; 138(Suppl. 1): 54–70. https://doi.org/10.1111/jnc.13588
4. Mikhaylova N.M., Gavrilova S.I. Alzheimer’s disease center: innovation model of outpatient assistance for the elderly patients with cognitive disorders and dementia. Psikhiatriya. 2015; (3): 42–51. (in Russian)
5. Yakhno N.N., Preobrazhenskaya I.S., Zakharov V.V., Stepkina D.A., Lokshina A.B., Mkhitaryan E.A., et al. Prevalence of cognitive impairments in neurological diseases: analysis of the activities of a specialized outpatient reception office. Nevrologiya, neyropsikhiatriya, psikhosomatika. 2012; (2): 30–5. (in Russian)
6. Snowden J.S. Snowden J.S., Thompson J.C., Stopford C.L., Richardson A.M., Gerhard A., et al. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain. 2011; 134(9): 2478–92. https://doi.org/10.1093/brain/awr189
7. Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011; 134(9): 2456–77. https://doi.org/10.1093/brain/awr179
8. Gregory C.A., Serra-Mestres J., Hodges J.R. Early diagnosis of the frontal variant of frontotemporal dementia: how sensitive are standard neuroimaging and neuropsychologic tests? Neuropsychiatry Neuropsychol. Behav. Neurol. 1999; 12(2): 128–35
9. Hodges J.R. Cognitive Assessment for Clinicians. Oxford: Oxford University Press; 2018.
10. Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., et al. Classification of primary progressive aphasia and its variants. Neurology. 2011; 76(11): 1006–14. https://doi.org/10.1212/WNL.0b013e31821103e6
11. Seeley W.W., Bauer A.M., Miller B.L., Gorno-Tempini M.L., Kramer J.H., Weiner M., et al. The natural history of temporal variant frontotemporal dementia. Neurology. 2005; 64(8): 1384–90. https://doi.org/10.1212/01.WNL.0000158425.46019.5C
12. Ng A.S., Rademakers R., Miller B.L. Frontotemporal dementia: a bridge between dementia and neuromuscular disease. Ann. N.Y. Acad. Sci. 2015; 1338(1): 71–93. https://doi.org/10.1111/nyas.12638
13. Tan R.H., Guennewig B., Dobson-Stone C., Kwok J.B., Kril J.J., Kiernan M.C., et al. The underacknowledged PPA-ALS: A unique clinicopathologic subtype with strong heritability. Neurology. 2019; 92(12): e1354–66. https://doi.org/10.1212/WNL.0000000000007146
14. Rowe J.B. Rowe J.B. Parkinsonism in frontotemporal dementias. Int. Rev. Neurobiol. 2019; 149: 249–75. https://doi.org/10.1016/bs.irn.2019.10.012
15. Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011; 134(9): 2456–77. https://doi.org/10.1093/brain/awr179
16. Nestor P.J., Altomare D., Festari C., Drzezga A., Rivolta J., Walker Z., et al. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur. J. Nucl. Med. Mol. Imaging. 2018; 45(9): 1509–25. https://doi.org/10.1007/s00259-018-4035-y
17. Jack C.R., Bennett D.A., Blennow K., Carrillo M.C., Feldman H.H., Frisoni G.B., et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016; 87(5): 539–47. https://doi.org/10.1212/WNL.0000000000002923
18. Goldman J.S., Farmer J.M., Wood E.M., Johnson J.K., Boxer A.M., Neuhaus J., et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology. 2005; 65(11): 1817–9. https://doi.org/10.1212/01.wnl.0000187068.92184.63
19. Shpilyukova Yu.A., Fedotova E.Yu., Illarioshkin S.N. Genetic diversity of frontotemporal dementia. Molekulyarnaya biologiya. 2020; 54(1): 17–28. https://doi.org/10.31857/S0026898420010139 (in Russian)
20. Shpilyukova Yu.A., Fedotova E.Yu., Abramycheva N.Yu., Illarioshkin S.N. Frequency of common genetic forms of frontotemporal dementia in a Russian cohort of patients. Meditsinskaya Genetika. 2020; 19(4): 30–2. https://doi.org/10.25557/2073-7998.2020.04.30-32 (in Russian)
21. Shpilyukova Yu.A., Fedotova E.Yu., Berdnikovich E.S., Konovalov R.N., Zakharova M.N., Grishina D.A., et al. C9ORF72-Associated frontotemporal dementia in the Russian population. Zhurnal nevrologii i psikhiatrii im. CC Korsakova. 2020; 120(9): 98–106. https://doi.org/10.17116/jnevro202012009198 (in Russian)
22. Shpilyukova Y., Fedotova E., Abramycheva N., Grishina D., Seliverstova E., Illarioshkin S. Frequency of GRN‐associated cases in a Russian cohort of patients with frontotemporal dementia. Alzheimer’s & Dementia. 2021; 17: e051043. https://doi.org/10.1002/alz.051043
23. Hsiung G.Y., Feldman H.H. GRN frontotemporal dementia. In: GeneReviews®[Internet]. Seattle: University of Washington, Seattle; 1993–2022.
24. Brutyan A.G., Brutyan A.G., Korepina O.S., Abramova A.A., Belyakova-Bodina A.I. The role of electroencephalography in the diagnosis of Creutzfeldt–Jakob disease. Nervnye bolezni. 2019; (4): 24–31. https://doi.org/10.24411/2226-0757-2019-12133 (in Russian)
25. Korhonen V.E., Solje E., Suhonen N.M., Rauramaa T., Vanninen R., Remes A.M., et al. Frontotemporal dementia as a comorbidity to idiopathic normal pressure hydrocephalus (iNPH): a short review of literature and an unusual case. Fluids Barriers CNS. 2017; 14(1): 10. https://doi.org/10.1186/s12987-017-0060-7
26. Bastiaansen A.E., van Steenhoven R.W., de Bruijn M.A., Crijnen Y.S., van Sonderen A., van Coevorden-Hameete M.H., et al. Autoimmune encephalitis resembling dementia syndromes. Neurol. Neuroimmunol. Neuroinflamm. 2021; 8(5): e1039. https://doi.org/10.1212/NXI.0000000000001039
27. Ducharme S., Bajestan S., Dickerson B.C., Voon V. Psychiatric presentations of C9orf72 mutation: what are the diagnostic implications for clinicians? J. Neuropsychiatry. Clin. Neurosci. 2017; 29(3): 195–205. https://doi.org/10.1176/appi.neuropsych.16090168
28. Ducharme S., Ducharme S., Dols A., Laforce R., Devenney E., Kumfor F., et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain. 2020; 143(6): 1632–50. https://doi.org/10.1093/brain/awaa112
29. Portugal M.D., Marinho V., Laks J. Pharmacological treatment of frontotemporal lobar degeneration: systematic review. Braz. J. Psychiatry. 2011; 33(1): 81–90. https://doi.org/10.1590/S1516-44462011000100016
30. Nardell M., Tampi R.R. Pharmacological treatments for frontotemporal dementias: a systematic review of randomized controlled trials. Am. J. Alzheimers. Dis. Other Demen. 2014; 29(2): 123–32. https://doi.org/10.1177%2F1533317513507375
31. Buoli M., Serati M., Caldiroli A., Galimberti D., Scarpini E., Altamura A.C. Pharmacological management of psychiatric symptoms in frontotemporal dementia: a systematic review. J. Geriatr. Psychiatry. Neuro. 2017; 30(3): 162–9. https://doi.org/10.1177%2F0891988717700506
32. Trieu C., Gossink F., Stek M.L., Scheltens P., Pijnenburg Y.A., Dols A. Effectiveness of pharmacological interventions for symptoms of behavioral variant frontotemporal dementia: a systematic review. Cogn. Behav. Neurol. 2020; 33(1): 1–5. https://doi.org/10.1097/WNN.0000000000000217
33. Callegari I., Mattei C., Benassi F., Krueger F., Grafman J., Yaldizli Ö., et al. Agomelatine improves apathy in frontotemporal dementia. Neurodegener. Dis. 2016; 16(5-6): 352–6. https://doi.org/10.1159/000445873
34. Finger E.C., MacKinley J., Blair M., Oliver L.D., Jesso S., Tartaglia M.C., et al. Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability. Neurology. 2015; 84(2): 174–81. https://doi.org/10.1212/WNL.0000000000001133
35. Huey E.D., Garcia C., Wassermann E.M., Tierney M.C., Grafman J. Stimulant treatment of frontotemporal dementia in 8 patients. J. Clin. Psychiatry. 2008; 69(12): 1981. https://doi.org/10.4088/jcp.v69n1219a
36. Jesso S., Morlog D., Ross S., Pell M.D., Pasternak S.H., Mitchell D.G., et al. The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. Brain. 2011; 134(9): 2493–501. https://doi.org/10.1093/brain/awr171
37. Kimura T., Hayashida H., Furukawa H., Takamatsu J. Pilot study of pharmacological treatment for frontotemporal dementia: effect of Yokukansan on behavioral symptoms. Psychiatry Clin. Neurosci. 2010; 64(2): 207–10. https://doi.org/10.1111/j.1440-1819.2010.02072.x
38. Pardini M., Serrati C., Guida S., Mattei C., Abate L., Massucco D., et al. Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: a proof-of-concept study. Neurodegener. Dis. 2015; 15(1): 58–62. https://doi.org/10.1159/000369811
39. Boxer A.L., Knopman D.S., Kaufer D.I., Grossman M., Onyike C., Graf-Radford N., et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013; 12(2): 149–56. https://doi.org/10.1016/S1474-4422(12)70320-4
40. Diehl‐Schmid J., Förstl H., Perneczky R., Pohl C., Kurz A. A 6‐month, open‐label study of memantine in patients with frontotemporal dementia. Int. J. Geriatr. Psychiatry. 2008; 23(7): 754–9. https://doi.org/10.1002/gps.1973
41. Vercelletto M., Boutoleau-Bretonnière C., Volteau C., Puel M., Auriacombe S., Sarazin M., et al. Memantine in behavioral variant frontotemporal dementia: negative results. J. Alzheimers. Dis. 2011; 23(4): 749–59. https://doi.org/10.3233/JAD-2010-101632
42. Gu X.H., Xu J., Wei C.S. P3‐303: Memantine in patients with behavioral variant frontotemporal dementia: An open‐label pilot study. Alzheimer’s & Dementia. 2015; 11(7S Pt. 16): P751–3. https://doi.org/10.1016/j.jalz.2015.06.1677
43. Lebert F., Stekke W., Hasenbroekx C., Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement. Geriatr. Cogn. Disord. 2004; 17(4): 355–9. https://doi.org/10.1159/000077171
44. Moretti R., Torre P., Antonello R.M., Cazzato G., Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. Eur. Neurol. 2003; 49(1): 13–9. https://doi.org/10.1159/000067021
45. Rahman S., Robbins T.W., Hodges J.R., Mehta M.A., Nestor P.J., Clark L., et al. Methylphenidate (‘Ritalin’) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. 2006; 31(3): 651–8. https://doi.org/10.1038/sj.npp.1300886
46. Herrmann N., Black S.E., Chow T., Cappell J., Tang-Wai D.F., Lanctôt K.L. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am. J. Geriatr. Psychiatry. 2012; 20(9): 789–97. https://doi.org/10.1097/JGP.0b013e31823033f3
47. Moretti R., Torre P., Antonello R.M., Cattaruzza T., Cazzato G., Bava A. Rivastigmine in frontotemporal dementia. Drugs Aging. 2004; 21(14): 931–7. https://doi.org/10.2165/00002512-200421140-00003
48. Devanand D.P., Pelton G.H., D’Antonio K., Strickler J.G., Kreisl W.C., Noble J., et al. Low-dose Lithium treatment for agitation and psychosis in Alzheimer’s disease and Frontotemporal dementia: A case series. Alzheimer Dis. Assoc. Disord. 2017; 31(1): 73. https://doi.org/10.1097%2FWAD.0000000000000161
49. Swanberg M.M. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis. Assoc. Disord. 2007; 21(2): 164–6. https://doi.org/10.1097/wad.0b013e318047df5d
50. Ikeda M., Shigenobu K., Fukuhara R., Hokoishi K., Maki N., Nebu A., et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement. Geriatr. Cogn. Disord. 2004; 17(3): 117–21. https://doi.org/10.1159/000076343
51. Furlan J.C., Henri-Bhargava A., Freedman M. Clomipramine in the treatment of compulsive behavior in frontotemporal dementia: a case series. Alzheimer Dis. Assoc. Disord. 2014; 28(1): 95–8. https://doi.org/10.1097/WAD.0b013e318265c104
52. Shinagawa S., Nakajima S., Plitman E., Graff-Guerrero A., Mimura M., Nakayama K., et al. Non-pharmacological management for patients with frontotemporal dementia: a systematic review. J. Alzheimers. Dis. 2015; 45(1): 283–93. https://doi.org/10.3233/jad-142109
53. Mioshi E., Bristow M., Cook R., Hodges J.R. Factors underlying caregiver stress in frontotemporal dementia and Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 2009; 27(1): 76–81. https://doi.org/10.1159/000193626
54. Chow T.W., Pio F.J., Rockwood K. An international needs assessment of caregivers for frontotemporal dementia. Can. J. Neurol. Sci. 2011; 38(5): 753–7. https://doi.org/10.1017/S0317167100054147
55. Luscombe G., Brodaty H., Freeth S. Younger people with dementia: diagnostic issues, effects on carers and use of services. Int. J. Geriatr. Psychiatry. 1998; 13(5): 323–30. https://doi.org/10.1002/(SICI)1099-1166(199805)13:5%3C323::AID-GPS768%3E3.0.CO;2-O
56. Rosness T.A., Haugen P.K., Engedal K. Support to family carers of patients with frontotemporal dementia. Aging Ment. Health. 2008; 12(4): 462–6. https://doi.org/10.1080/13607860802224334
57. Chemali Z., Withall A., Daffner K.R. The plight of caring for young patients with frontotemporal dementia. Am. J. Alzheimers Dis. Other Demen. 2010; 25(2): 109–15. https://doi.org/10.1177/1533317509352335
58. Tanabe H., Ikeda M., Komori K. Behavioral symptomatology and care of patients with frontotemporal lobe degeneration–based on the aspects of the phylogenetic and ontogenetic processes. Dement. Geriatr. Cogn. Disord. 1999; 10(Suppl. 1): 50–4. https://doi.org/10.1159/000051213
59. Yokota O., Fujisawa Y., Takahashi J., Terada S., Ishihara T., Nakashima H., et al. Effects of group-home care on behavioral symptoms, quality of life, and psychotropic drug use in patients with frontotemporal dementia. J. Am. Med. Dir. Assoc. 2006; 7(5): 335–7. https://doi.org/10.1016/j.jamda.2006.02.012
60. Wylie M.A., Shnall A., Onyike C.U., Huey E.D. Management of frontotemporal dementia in mental health and multidisciplinary settings. Int. Rev. Psychiatry. 2013; 25(2): 230–6. https://doi.org/10.3109/09540261.2013.776949
61. Carthery-Goulart M.T., Silveira A.D., Machado T.H., Mansur L.L., Parente M.A., Senaha M.L., et al. Nonpharmacological interventions for cognitive impairments following primary progressive aphasia: A systematic review of the literature. Dement. Neuropsychol. 2013; 7(1): 122–31. https://doi.org/10.1590/S1980-57642013DN70100018
62. Cotelli M., Manenti R., Ferrari C., Gobbi E., Macis A., Cappa S.F. Effectiveness of language training and non-invasive brain stimulation on oral and written naming performance in Primary Progressive Aphasia: A meta-analysis and systematic review. Neurosci. Biobehav. Rev. 2020; 108: 498–525. https://doi.org/10.1016/j.neubiorev.2019.12.003
63. Cheng S.T., Chow P.K., Song Y.Q., Edwin C.S., Chan A.C., Lee T.M., et al. Mental and physical activities delay cognitive decline in older persons with dementia. Am. J. Geriatr. Psychiatry. 2014; 22(1): 63–74. https://doi.org/10.1016/j.jagp.2013.01.060
64. Denkinger M.D., Nikolaus T., Denkinger C., Lukas A. Physical activity for the prevention of cognitive decline. Z. Gerontol. Geriatr. 2012; 45(1): 11–6. https://doi.org/10.1007/s00391-011-0262-6
Review
For citations:
Shpilyukova Yu.A., Fedotova E.Yu. Frontotemporal dementia: clinical features, diagnosis, and treatment. L.O. Badalyan Neurological Journal. 2022;3(1):14-24. (In Russ.) https://doi.org/10.46563/2686-8997-2022-3-1-14-24
Views:
1000
Email this article 
